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Depletion attractionng surfactant for the air–water interface, resulting in decreased surfactant
adsorption and increased surface tension. Polyethylene glycol (PEG) and other hydrophilic polymers restore
the normal rate of surfactant adsorption to the interface, which re-establishes low surface tensions on
compression. PEG does so by generating an entropic depletion attraction between the surfactant aggregates
and interface, reducing the energy barrier to adsorption imposed by the albumin. For a ﬁxed composition of
10 g/L (1% wt.), surfactant adsorption increases with the 0.1 power of PEG molecular weight from 6 kDa–
35 kDa as predicted by simple excluded volume models of the depletion attraction. The range of the
depletion attraction for PEG with a molecular weight below 6 kDa is less than the dimensions of albumin and
there is no effect on surfactant adsorption. PEG greater than 35 kDa reaches the overlap concentration at 1%
wt. resulting in both decreased depletion attraction and decreased surfactant adsorption. Fluorescence
images reveal that the depletion attraction causes the surfactant to break through the albumin ﬁlm at the
air–water interface to spread as a monolayer. During this transition, there is a coexistence of immiscible
albumin and surfactant domains. Surface pressures well above the normal equilibrium surface pressure of
albumin are necessary to force the albumin from the interface during ﬁlm compression.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionLung surfactant (LS) lines the alveolar air–liquid interface and
lowers the interfacial tension in the lungs [1,2]. The surface tension
control imposed by LS is likely compromised during acute respiratory
distress syndrome (ARDS), which afﬂicts 140,000 people annually in
the USwith a 40%mortality rate [2,3]. The clinical similarities between
ARDS and neonatal RDS suggest that the lack of functional surfactant
that causes NRDS might be a common factor. However, replacement
surfactant treatments that have been successful in treating NRDS have
been disappointing when used to treat ARDS [4]. The replacement LS,
as does the native surfactant, loses its ability to reduce surface tension
and is said to be “inactivated” [2,5–7]. In addition to inactivated LS,
serum and inﬂammatory protein levels in the bronchial and alveolar
ﬂuid of ARDS patients are elevated [2,8–11]. In vitro, there is an ARDS-
like depression of LS activity when serum proteins are added to a
surfactant-covered interface [12], surfactant is added to a serum-
covered interface [13] or both surfactant and serum proteins are
presented simultaneously [14]. Surfactant inactivation caused by
serum leakage into the alveoli is hypothesized to be a contributing
factor to the lack of success in ARDS treatment [15,16], although the
detailed biophysical mechanisms of inactivation are unknown.1 805 893 4731.
asadzinski).
ll rights reserved.We have shown that one cause of surfactant inactivation is the
inhibition of surfactant adsorption to the air–water interface caused by
the competitive adsorption of serum proteins such as albumin,
immunoglobulin and ﬁbrinogen [12,13,17,18]. Many serum proteins
are surface-active and have a surface pressure,Π, (Π=γw−γ; γw is the
surface tension of a clean air–water interface, 72 mN/m, and γ the
measured surface tension) that is a logarithmic function of protein
concentration up to a saturation concentration, which is ~1 mg/mL for
albumin [12,19]. The surface pressure at the saturation concentration for
albumin and many other serum proteins is between 18 and 25 mN/m
(γ~47–54mN/m) [12,19], which ismuch lower thanΠ~70 (γnear zero)
required for proper respiration. Albumin adsorbed at the alveolar air–
water interface induces a steric and electrostatic energy barrier to
LS adsorption [12,13,17,18,20], which inhibits surfactant transport to
the interface [17,21], thereby reducing surfactant adsorption. Insufﬁ-
cient surfactant at the interface does not allow the low surface tensions
required for proper lung function to be reached and the work of brea-
thing increases. This increases the potential for further inﬂammation
and injury, consistent with the development of ARDS.
Several hydrophilic polymers, including polyethylene glycol (PEG),
dextran, and hyaluronic acid enhance the ability of clinical surfactants
to resist inactivation by serum proteins and other substances in vitro
[13,14,17,18,20,22–25]. Lung function of animals with lung injury is
markedly improved when polymers are added to clinical surfac-
tants used for treatment of NRDS [26–29]. Theory [6,7,17] and experi-
ment [13,18] suggest that hydrophilic polymers induce a “depletion
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interface, thereby increasing LS adsorption to the interface and
restoring surfactant function [13,18]. The depletion attraction arises
from the decrease in the polymer excluded volume as the surfactant
aggregates approach the interface [17,30,31]; in a dilute solution, the
translational entropy of non-entangling, non-adsorbing polymer
molecules increases with increasing solution volume [30]. The
increased entropy of the polymer molecules acts like an attractive
force between the surfactant aggregates and the interface (or between
the aggregates) that pushes the surfactant toward the interface,
thereby enhancing adsorption [13,17,30,31,34].
The depletion attraction model provides quantitative predictions
regarding the molecular weight dependence of PEG on adsorption (Eqs.
(1–5)) [17]. At low polymer concentrations, the magnitude of the
depletion attraction increases linearly with the polymer weight fraction
below the entanglement concentration of the polymer [13,17,30,31,34].
However, the range of the depletion attraction is limited by the
hydrodynamic diameter of the polymer [17,30,31,34]. If the molecular
weight, and hence the diameter of the polymer, is too small, the range of
the depletion attraction may not overlap the range of the repulsive
electrostatic and steric interactions. As a result, a minimum molecular
weight is necessary to enhance surfactant adsorption. For molecular
weights above thisminimum, the depletion attraction for a givenweight
fraction increases weakly (MW0.1) with the molecular weight of the
polymer [17] below the entanglement concentration (which also
depends on molecular weight). Above the polymer entanglement
concentration, the magnitude of the depletion attraction decreases
because the excluded volume effects and the entropy increase of the
polymer decrease, leading to less enhancement of surfactant adsorption
[35,36].
To test these predictions of the depletion attraction/energy barrier
model, we examine the inactivation induced by albumin of the clinical
lung surfactant, Survanta, and theenhancementof surfactant adsorption
inducedbyPEGwithmolecularweights ranging from1.45kDa–200 kDa.
Several studies have shown that 10 kDa PEG reverses surfactant
inactivation both in vitro and in vivo [6,18,24,27]. We previously showed
that surfactant adsorption increased exponentially with the weight
fraction of 10 kDaPEG, but only linearlywith surfactant concentration as
predicted by the depletion attraction theories and the modiﬁed
Smolukowski equations (Eqs. (1–5)) [13,17]. Here we show that there
is a minimum molecular weight of PEG needed to reverse inhibition;
PEG below 6 kDa does not reverse inhibition because the range of the
depletion attraction, (twice the polymer radius of gyration), is less than
the thickness of the albumin layer. At 1%wt., PEG above 100 kDa is above
the overlap concentration, at which the depletion interaction decreases
and the solution viscosity increases, both of which reduce surfactant
adsorption. For 1% wt. PEG, surfactant adsorption is proportional to
(MW)0.1 from 6–35 kDa as predicted by the depletion attraction model.
Fluorescence images show that surfactant must break through the
albumin ﬁlm to the air–water interface to spread as a monolayer and
lower surface tension; in the absence of polymer, the surfactant cannot
reach the interface due to the albumin. Once surfactant has broken
through locally, a coexistence of immiscible albumin and surfactant
domains are present at the interface and the polymer increases the
displacement of albumin for surfactant at the interface. Upon
compression, the albumin cannot withstand high surface pressures
and is removed in favor of the surfactant; surface pressures well above
the 18–25 mN/m equilibrium surface pressure of albumin [12,19] are
necessary to completely force it from the interface.
2. Theory
The effects of albumin on surfactant adsorption can be quantiﬁed
using a variant of the classic Smolukowski analysis of colloid stability
[17,37]. Charged, surface-active serum proteins adsorbed at an inter-
face induce an electrostatic and steric barrier to surfactant adsorp-tion at that interface, similar in magnitude to the energy barriers
responsible for colloidal stability againstﬂocculation [38]. The addition
of hydrophilic polymers generates a “depletion attraction” which
offsets the otherwise repulsive potential induced by the proteins at the
interface.
The change in surfactant interfacial concentration with time, dCdt , is
driven by the gradient of a generalized chemical potential of surfac-
tant in the subphase. The presence of a charged protein layer adsorbed
to the interface induces a potential energy barrier to surfactant
adsorption, as in the Smolukowski theory of colloid stability [17]:
dC
dt
= C0
Deff
pt
 1=2
exp ½− Vmaxð Þ=kBT ð1Þ
C0 is the bulk surfactant concentration, Deff is the effective surfactant
diffusivity, Vmax is the maximumheight of the potential energy barrier
(located a distance l from the interface), kB is Boltzmann's constant
and T is the temperature. The magnitude and location of the potential
energy barrier are both important when determining the impacts on
surfactant adsorption. The polymer generated depletion attraction
modiﬁes this the potential energy barrier to enhance surfactant
adsorption. The potential energy barrier results from several effects
which are taken to be additive:
Vmaxi E1−E0ð Þ +PDA + EElect +W ð2Þ
(E1−E0) is the energy difference between surfactantmolecules at the
interface and in the bulk, which drives surfactant adsorption to a clean
interface. This is opposed by a steric term,ΠΔA, which accounts for the
energy necessary to clear an interfacial area, ΔA, of serum protein at a
surface pressure of Π for surfactant adsorption. The repulsive double-
layer electrostatic potential, EElect, is due to the negatively charged
albumin and its magnitude depends on the ionic strength of the sub-
phase and the net distribution of charge at the interface and the
surfactant bilayers [21].
In the presence of non-adsorbing polymers such as PEG, these two
repulsive terms are offset by the depletion attraction, W. Moving a
large sphere of radius R (the surfactant aggregate) to within l of an
interface (or toward another large sphere) frees excluded volume for
the polymer of radius Rg, and thereby increases the polymer entropy,
leading to the depletion attraction [17,31]:
l V 2Rg : W = −3 R=Rg
 
/pkBT 1− l=2Rg
  2
l N 2Rg : W = 0
ð3Þ
/p is the volume fraction of the polymer in solution. The depletion
attraction is very short-ranged and has no effect for distances greater
than the polymer diameter. As the surfactant particle comes into con-
tact with the air–water interface, Wmax=−3(R/Rg)/pkBT. For the PEG
used here, Rg ranges from 1.5 nm (1.45 kDa PEG) to 22.7 nm (200 kDa
PEG). Bovine serum albumin is a prolate spheroid of dimensions
4×4×14 nm and self assembles at the air–water interface with a
thickness of 4 nm; infrared spectroscopy measurements suggest that
denaturation of the albumin does not occur on a time scale of hours or
days [39]. The surfactant aggregates are of order μm in diameter
[17,40]; hence the depletion attraction is signiﬁcantly greater for the
surfactant aggregates than for albumin. Due to its entropic origin, the
depletion attraction is independent of the surfactant, protein and
polymer as long as the polymer does not adsorb to the protein,
surfactant or interface. This explains why PEG [6,13,20,27], dextran,
[7,14] and hyaluronan [25] are all effective at enhancing surfactant
adsorption.
Eqs. (1–3) predict that the net rate of surfactant adsorption is
dominated by themagnitude of the energy barrier, Vmax, and hence on
W, the magnitude of the depletion attraction [13,17,18]. Experimen-
tally, we compare the rate of surfactant adsorption with albumin and
PEG in the subphase, dC=dt Alb + Poly, to surfactant adsorption from a
2034 P.C. Stenger et al. / Biochimica et Biophysica Acta 1778 (2008) 2032–2040clean subphase, dC=dt. From Eqs. (1–3), the enhancement in surfac-
tant adsorption due to the polymer should scale as:
dC=dtAlb + Poly
dC=dt
i exp
− PDA + EElect +Wmaxð Þ
kBT
 	
= exp
−PDA + EElect
kBT
 	
exp 3
R
Rg
/p
 	 ð4Þ
As the subphase concentration of albumin is ﬁxed, (ΠΔA+EElect) is
constant. We have previously veriﬁed the exponential dependence of
surfactant adsorption on polymer volume fraction (ϕp) at a ﬁxed
molecular weight (constant Rg) and surfactant aggregate size (R) [13].
Here we vary the molecular weight, and hence Rg, at a constant weight
fraction of polymer. Water is a good solvent for PEG over the entire
experimental range and several authors have shown Rg=αMW0.55
where MW is the polymer molecular weight and α is a constant
[41,42]. In Eq. (4), /peNpR3g=V in which Np is the number of polymer
molecules in a volume V. For a ﬁxed polymer weight fraction of ρ,
Np = qV=MW , hence the depletion attraction for PEG should scale as
Wmax~MW0.1. The range of the depletion attraction is also proportional
to Rg and hence should increase asMW0.55.
3. Materials and methods
The clinical replacement surfactant Survanta (Abbott Laboratories, Columbus, Ohio)
was a generous gift of the Santa Barbara Cottage Hospital nursery. Survanta is an
organic extract of minced bovine lungs that has been fortiﬁed with dipalmitoylpho-
sphatidylcholine (DPPC), tripalmitin and palmitic acid. It contains 80–90 wt.%
phosphatidylcholine, of which, ~70 wt.% is saturated DPPC, approximately 5 wt.%
negatively charged phospholipids, primarily phosphatidylglycerol and phosphatidyl-
serine, and about 10 wt.% palmitic acid [40,43]. There is b2 wt.% of the lung surfactant
speciﬁc proteins SP-B (0.04–0.13 wt. %) [44] and SP-C (0.9–1.65 wt.%) [40,43,45].
Survanta and other clinical lung surfactants form multi-micron bilayer aggregates in
buffered saline solution [40] and Survanta adsorbs to a clean interface from solution as a
combination of monolayer and multilayers [46]. Polyethylene glycol (PEG) of 1.45 kDa,
3.35 kDa, 6 kDa, 10 kDa, 20 kDa, 35 kDa, 100 kDa and 200 kDa and bovine serum
albumin were obtained from Sigma (St. Louis, MO) and used as received.
Isotherms were recorded at 25 °C (No signiﬁcant changes are seen from 23–37 °C
[46]) using a custom stainless steel ribbon trough (Nima, Coventry, England) designed
to minimize ﬁlm leakage at high surface pressures (low surface tensions). Surface
pressure was monitored during compression and expansion using a ﬁlter paper
Wilhelmy plate. The trough has a surface area of 130 cm2, a subphase volume of 150 mL
and a typical compression/expansion cycle took 8 min (~0.42 cm2/s). Albumin and
polymer were dissolved in the same buffer used as the subphase (NaCl 150 mM, CaCl2
2 mM, NaHCO3 0.2 mM and pH=7) at the stated concentrations for all experiments. To
initiate each experiment, a saline buffer subphase containing albumin and polymer was
added to the Langmuir trough and allowed to equilibrate for 10 min; for albumin
containing subphases, the surface pressure was ~18 mN/m, consistent with the known
surface activity of albumin [12,19]. Survanta was diluted in the same buffer to a lipid
concentration of 2 mg/mL and was deposited as microliter drops from a syringe by
touching the drop to the air/water interface of the open trough. The drops primarily
wound up in the subphase adjacent to the interface; drop diffusion into the subphase
was easily monitored as the Survanta usually was labelled with a ﬂuorescent dye. The
drops did not spread appreciably at the interface, in contrast to when surfactants are
spread from organic solvents; essentially all of the Survanta adsorbed from the
subphase. No stirring of the subphase was used and the ﬁrst compression began 20 min
after deposition of a ﬁxed quantity of Survanta. The amount of Survanta chosen for the
inhibition experiments was such that collapse would occur at about 50% trough
compression in the absence of albumin or PEG; this was then held ﬁxed for all
remaining experiments except where noted.
A Nikon Optiphot optical microscope (Nikon, Tokyo, Japan) was positioned above
the trough with either a 10× or 50× extra long working distance objective designed for
ﬂuorescent light [47–50]. Full-length movies and individual frames were recorded
directly to computer (Moviestar, Mountain View, CA). Contrast in the images was due to
segregation of 1% mol ﬂuorescent lipid Texas Red-DHPE (Molecular Probes, Eugene, OR)
which causes the Survanta monolayer to appear a light grey in images [46]. Larger
aggregates of Survanta have signiﬁcantly more dye and appear bright white, leading to
an overall mottled texture for the surfactant ﬁlm. The albuminwas not labeled, does not
ﬂuoresce and appears black in the images.
Zero-shear viscosities at 25 °C were measured with a capillary viscometer (#100
C503, Cannon Instrument Co., State College, PA) calibrated for a viscosity range of 0.8 to
100 mPa-s (water has a viscosity of ~1 mPa-s at 25 °C) [51]. Samples containing PEG of
varyingmolecular weightswere dissolved in buffer (NaCl 150mM, CaCl2 2mM, NaHCO3
0.2 mM and pH=7). Three measurements were taken and averaged for each sample
with a typical standard deviation of 0.7%. Overlap is generally taken to be at polymer
concentrations that increase the solution viscosity by more than a factor of two [52].4. Results
Fig. 1a shows a typical compression–expansion cyclic isotherm for
800 μg of the clinical lung surfactant, Survanta, spread on a clean saline
buffered subphase (noalbuminorPEG) [13,46]. The isothermtraces over
itself on subsequent cycles, and on compression exhibits a characteristic
shoulder at Π~40 mN/m which corresponds to rearrangement of the
unsaturated lipids and surfactant proteins SP-B and SP-C in theﬁlm [46].
On further compression, the surface pressure rises abruptly to the
collapse pressure,Πmax~65 mN/m, where the ﬁlm begins to “collapse”
and forms cracks and folds [13,46]. Film collapse determines the
minimum surface tension possible for a given surfactant. The hysteresis
between compression and expansion cycles is typical of Survanta and
other clinical and natural lung surfactant isotherms [2,53] and is due to
the partial re-adsorption of the collapse structures into the monolayer
[12]. On a clean subphase, re-expanding the interface after monolayer
collapse leads to a rapid drop in surface pressure to about 5–10 mN/m
which is maintained until compression is resumed [2,46]. In general,
collapse structures do not re-adsorb to the interface until the surface
pressure is well below the collapse pressure, resulting in the compres-
sion and expansion hysteresis [12]. There is no signiﬁcant change in
Survanta isotherms from 23–37 °C [46].
However, when the same amount of Survanta (800 μg) is deposited
on a buffered subphase containing 2mg/mL albumin and 1%wt. PEG of
molecular weight 1.45 kDa (Fig. 1b, black curve), the surface pressure
does not increase above 35 mN/m even at the smallest trough area.
Albumin concentrations in ARDS alveolar ﬂuid may reach 100 mg/mL
with an average concentration of 25 mg/mL [10]. The concentrations
used here are signiﬁcantly lower than typically found in ARDS patients,
but are at or above the saturation concentration at which the albumin
surface pressure no longer increases with concentration [12]. The
characteristic shoulder and collapse plateau on compression seen in
Fig. 1a cannot be reached with albumin in the subphase, despite the
presence of low molecular weight PEG. Both the compression and
expansion isotherm are not different than that of albumin alone
(Fig.1b, red curve). Theminimum surface pressure (~15mN/m) during
expansion of the Survanta–albumin–1.45 kDa PEG isotherm (Fig. 1b,
black curve) is higher than Fig. 1a and is set by the re-adsorption of
albumin to the interface at its saturation surface pressure. This shows
that Survanta on an albumin subphase does not adsorb to the interface
in appreciable quantity and that 1.45 kDa PEG does not increase
adsorption. Survanta inactivation under these conditions results from
an inability of the surfactant to adsorb to the interface.
In contrast to 1.45 kDa PEG, a 1% wt. 10 kDa PEG and 2 mg/mL
albumin subphase (Fig. 1c) restores the isotherm to that of the clean
interface after two compression–expansion cycles (Fig. 1a), showing
that the higher molecular weight PEG reverses surfactant inactivation.
The compression cycle in Fig. 1c displays the characteristic shoulder
at Π~40 mN/m and a collapse plateau at Πmax~65 mN/m at similar
trough areas as Fig. 1a, conﬁrming that PEG 10 kDa does not alter the
properties of the surfactant monolayer. Rather, the PEG enhances the
adsorption of surfactant to the interface and the displacement of
albumin from the interface. The only difference between Fig. 1a and c
is that the expansion cycle in Fig. 1c has a minimum surface pressure
of about 15 mN/m (vs. 5–10 mN/m in Fig. 1a). While the increased
minimum surface pressure could be set by albumin re-adsorption at
its equilibrium surface pressure, Survanta on subphases containing
PEG but no albumin also shows an increased minimum surface pres-
sure during the expansion. For example, Survanta (800 μg) deposited
onto a subphase containing 5% wt. 10 kDa PEG (no albumin) shows a
minimum surface pressure during expansion of ~23 mN/m suggesting
that the increased minimum surface pressure in Fig. 1c is a result of
PEG-enhanced surfactant adsorption (data not shown). The restora-
tion of the Survanta isotherm (Fig.1a) during subsequent compression
cycles in Fig. 1c shows that the rate of surfactant adsorption to
the interface is sufﬁcient to prevent any appreciable albumin re-
Fig.1. Cyclic isotherms of Survanta on buffered saline subphase containing albumin and/or polymer. (a) 800 μg Survanta on a clean buffered saline subphase (no albumin or polymer).
On compression, the isotherm exhibits a characteristic shoulder at 40 mN/m. The collapse plateau atΠmax~65 mN/m determines the maximum surface pressure (minimum surface
tension) possible for a given surfactant. On expansion, the surface pressure immediately drops to 10 mN/m; lung surfactant isotherms exhibit signiﬁcant hysteresis between the
compression and expansion parts of the cycle as collapsed material re-adsorbs at lower surface pressures [12]. (b) Black curve: 800 μg Survanta deposited onto a saline buffer
subphase containing 2 mg/mL albumin and 1% wt. 1.45 kDa PEG. The characteristic shoulder and collapse plateau on compression seen in (a) cannot be reached with albumin in the
subphase, despite the presence of low molecular weight PEG. Red Curve: The isotherm for the albumin subphase, with no Survanta or PEG. The two curves trace over each other,
indicating that the interfacial ﬁlm is dominated by albumin and the surfactant has been prevented from reaching the surface as shown in the ﬂuorescence image, Fig. 2b. (c) 800 μg
Survanta on saline buffer containing 2 mg/mL albumin and 1% wt. 10 kDa PEG. The characteristic shoulder and collapse plateau have been restored at similar trough areas as (a) with
little change in surface pressure showing that the presence of 10 kDa PEG completely reverses the surfactant adsorption inhibition. The only difference is that the expansion cycle in
Fig. 1c has a minimum surface pressure that is about 15–20 mN/m (vs. 5–10 mN/m in Fig. 1a) which is a result of enhanced surfactant adsorption during the expansion due to 10 kDa
PEG. Compression cycles are labeled 1–4 in chronological order. (d) 800 μg Survanta on saline buffer containing 2 mg/mL albumin and 1% wt. 200 kDa PEG. In this case, the
characteristic shoulder and collapse plateau of (a) are obtained at higher trough compression indicating that 1 wt. % 200 kDa PEG partially reverses the adsorption inhibition.
Compression cycles are labeled 1–4 in chronological order.
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(Fig. 1d) though not as efﬁciently as 10 kDa PEG (Fig. 1c). Fig. 1d shows
that the characteristic shoulder at Π~40 mN/m and the collapse
plateau at Πmax~68 mN/m are present, but at a signiﬁcantly smaller
trough area (greater compression) indicating that less surfactant has
adsorbed to the interface [13] than in Fig. 1a or c.
Fig. 2a shows a ﬂuorescence micrograph of a typical interface after
Survanta adsorption. Survanta (doped with 1% mol Texas Red-DHPE)
adsorbs to the interface of a saline buffer subphase as a mixture of
monolayers (mottled light gray and dark gray) typical of a phase
separated lipid/protein monolayer [49] along with bright, three-
dimensional aggregates that appear to be attached to the interface
[46]. This characteristic mottled texture is found at all surface pres-
sures from 0 to collapse [49] and is indicative of the coexistence of
solid-like, semi-crystalline domains (darker gray) and less ordered,
ﬂuid domains (lighter gray) [54]. In contrast, Fig. 2b shows that images
of Survanta on an albumin subphase consist of isolated, out-of-focus
bright regions with an overall dark homogeneous background. While
the Survanta aggregates appear to be able to diffuse toward the
interface, they apparently cannot reach the interface and spread as a
monolayer due to the adsorbed albumin ﬁlm. The Survanta does not
form a monolayer at the interface and the surface pressure remains
low throughout the compression/expansion cycle. The interfacial ﬁlm
is dominated by albumin; the albumin prevents the surface pressure
from increasing by preventing surfactant adsorption to the interface.Fig. 2c–j show the gradual displacement of albumin from the
interface by Survanta in the presence of 200 kDa PEG in the subphase.
Survanta was deposited onto a subphase containing albumin and 1%
wt. 200 kDa PEG and the interface was compressed and expanded.
Images from the ﬁrst cycle show a featureless albumin-covered inter-
face at low surface pressure (Fig. 2c, Π=18) and out of focus bright
spots at a higher surface pressure (Fig. 2d, Π=38), indicating that
Survanta aggregates approach the albumin-covered interface but
cannot spread. It appears from these and other images that break-up
of the Survanta aggregates from bilayer to monolayer is required for
the aggregates to reach the air–water interface. At maximum com-
pression on the ﬁrst cycle, (Fig. 1d,1) themaximum surface pressure is
~40 mN/m, which is similar to an albumin-covered interface (Fig. 1b).
However, images from the second cycle show a coexistence between
Survanta (mottled bright texture) and albumin (black) with a well-
deﬁned interface between the materials. Survanta has broken through
the albumin ﬁlm, perhaps through defects in the monolayer [55] and
occupies an increasing fraction of the interfacial area (See Movie #1 in
Supplemental Materials). The coexistence between the extended
(N1000 μm) interfacial domains of Survanta and albumin occurs both
during compression (Fig. 2e,Π=18) and expansion (Fig. 2f,Π=16) of the
ﬁlm. Even though the surface pressure reaches a Πmax of ~55 mN/m
(Figs.1d, 2),which ismuchgreater than theequilibrium surfacepressure
of a 2 mg/ml albumin solution (~20 mN/m), albumin remains at the
interface. The removal of albumin from the interface may be limited
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(See Movie #2 in Supplemental Materials). However, as Survanta can
maintain amuch higher dynamic surface pressure on compression than
albumin, after repeated compressions the albumin is forced from the
surface into the subphase at surface pressures of 50–60 mN/m (See
Movie#3 in SupplementalMaterials). Additional Survanta likelyadsorbsfrom the bright aggregates that appear to be attached to the interface to
occupy the new interface created as the trough expands.
Images from the third cycle show Survanta/albumin coexistence at
low surface pressure (Fig. 2g, Π=26) but now adequate surfactant
has adsorbed to raise the maximum surface pressure to 65 mN/m
(Figs. 1d, 3) which is sufﬁcient to force all of the albumin from the
Fig. 3. Fourth cycle compression isotherms of (a) varying concentrations of Survanta on
a clean buffered subphase and (b) 800 μg Survanta on a saline buffered subphase
containing 2 mg/mL albumin and 1% wt. PEG of varying molecular weights. (a) ▽3 μg
Survanta; △ 8 μg Survanta; D 30 μg Survanta; w 80 μg Survanta; ○ 300 μg Survanta;
□ 800 μg Survanta; At a given surface pressure, the isotherms are translated unchanged
from low trough area to high trough area with increasing Survanta concentration
(note the characteristic shoulder at ~40 mN/m and the collapse plateau at ~65 mN/m).
The interface becomes saturated for concentrations greater than about 300 μg; the
800 μg isotherm is not displaced signiﬁcantly to higher trough areas. Increasing sur-
factant adsorption to the interface leads to this gradual shift of the isotherms from left
to right. (b)□ Survanta only;○ Survanta–albumin;△ Survanta–albumin–PEG 1.45 kDa;
▽ Survanta–albumin–PEG 3.35 kDa; ◁ Survanta–albumin–PEG 6 kDa; w Survanta–
albumin–PEG 35 kDa; D Survanta–albumin–PEG 100 kDa. Except for PEG 1.45 kDa, the
presence of 1% wt. PEG in the subphase shifts the isotherms to higher trough areas, the
same effect as increasing the Survanta concentration in (a). For readability, 10 kDa and
20 kDa curves were omitted as they nearly overlap with 35 kDa; 200 kDa was similarly
omitted as it overlapped with 100 kDa. Cumulative results from all experiments are
presented in Fig. 4. The shaded area denotes the trough area over which the surface
pressure was averaged for each PEG molecular weight to obtain the relative surfactant
adsorption plotted in Fig. 4.
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third cycle expansion (Fig. 2h,Π=15). On the fourth cycle, the mottled
Survanta texture similar to Fig. 2a is seen exclusively at all surface
pressures (Fig. 2i, Π=43) and the system forms a collapse plateau
(Fig. 2j, Π=68). Due to the extremely short collapse plateau, the
cracks and folds typically associated with ﬁlm collapse [13,46] are not
seen in the 200 kDa PEG system. Images from systems with a collapse
plateau similar in length to Survanta on a saline subphase (Fig. 1a)
such as 1% wt. 10 kDa PEG show cracks and folds. While the texture is
similar between Fig. 2a and h–j, the bright aggregates are signiﬁcantly
larger in Fig. 2h–j; the PEG-induced depletion attraction also leads to
ﬂocculation of the Survanta aggregates [17,40]. In addition to helping
the Survanta break through the albumin monolayer, the depletion
attraction helps maintain a larger reservoir of surfactant in close
proximity to the interface during collapse and re-adsorption cycles.
The mechanism of surfactant displacement of the albumin at the inter-
face is similar for all PEG molecular weights which restore surfactant
adsorption to the interface (6–200 kDa). The process is most easily
imaged for the 200 kDa PEG because it takes three compression–
expansion cycles to complete, images from 10 kDa PEG demonstrate a
similar surfactant displacement although here the albumin is elimi-
nated by the second cycle.
Fig. 3a shows the fourth cycle of compression isotherms for varying
amounts of Survanta deposited onto a clean saline subphase. The
characteristic shape of the isotherms in Fig. 3a are translated
unchanged (note the shape of the collapse plateau and the shoulder
at ~40 mN/m) from low to high trough area as the amount of Survanta
added to the trough is increased from 3 μg up to 800 μg. As the
relationship between surface pressure and area/molecule is ﬁxed for a
given surfactant composition and temperature, an increase in surface
pressure at a given trough area means that the total amount of
surfactant at the interface has increased [46]. Therefore increasing
surfactant adsorption translates the isotherm at a given surface
pressure from low to high trough area. Eventually, further increases in
surfactant concentration have diminishing effect (note the smaller
offset between 300 μg to 800 μg) as the adsorption saturates. Any
additional surfactant that does not adsorb to the monolayer remains
near the interface as bilayer aggregates as in Fig. 2; this suggests that
there is more material near the interface for the higher concentration
sample compared to the lower concentration sample.
Fig. 3b shows the effect of albumin on the isotherms is similar to
decreasing the Survanta concentration (Fig. 3a), even though the same
amount of Survanta (800 μg) was deposited to initiate each
experiment. The shifting of the isotherms conﬁrms that albumin
inhibits the adsorption of surfactant to the interface as predicted by
Eq. (1).With no added polymer, the isotherm of Survanta deposited on
a subphase containing albumin (Fig. 3b, circles) differs little from the
800 μg Survanta–albumin–PEG 1.45 kDa curve (Fig. 3b, up triangles),
or from that of albumin by itself (Fig.1b). In all the isotherms in Fig. 3b,
the minimum surface pressure during compression is about 15 mN/m
when albumin and PEG are present; this is set by some combination of
albumin and PEG-enhanced surfactant adsorption. Compressing theFig. 2. Fluorescence images of 800 μg Survanta spread at varying subphase compositions. Im
during compression. The image shows the mottled texture typical of a phase separated lipid
interface and partially in solution. (b) Survanta on a subphase containing 2 mg/mL albumi
background shows that Survanta aggregates come close to the interface, but cannot spread
subphase containing 2 mg/mL albumin and 1% wt. 200 kDa PEG in successive compression
supplementary materials. Row 2—First Cycle (c) Π=18 mN/m during compression. At low s
from adsorbing to the interface. (d) Π=38 mN/m during compression. Similar to (b), Survan
pressure well above the equilibrium spreading pressure of albumin (~20 mN/m). Row 3—Se
ﬁlm; extended (N1000 μm) immiscible Survanta (mottled gray) and albumin (black) domain
coexistence persists as the second cycle Πmax (~55 mN/m) is not sufﬁcient to squeeze out
domains exist at low surface pressure but are squeezed out at high surface pressure (Third
onward, only Survanta is observed in the ﬁlm. Row 5—Fourth Cycle (i)Π=43 mN/m during co
domains are signiﬁcantly larger in (h–j) due to the PEG induced depletion attraction leadi
compression. The ﬁlm reaches a collapse pressure similar to Fig. 1a.ﬁlm and comparing to ﬁlms of pure Survanta or pure albumin can
show the relative amount of Survanta and albumin in the ﬁlm. Fig. 3b
shows that even though 800 μg of Survanta was added to the
subphase, as well as 1% wt. 1.45 kDa PEG, the albumin preventsages are 1023 μm by 789 μm. (a) Survanta on a clean, buffered subphase atΠ=43 mN/m
/protein monolayer. The bright spots are Survanta aggregates partially adsorbed to the
n at Π=25 mN/m during compression. The weak out of focus ﬂuorescence on a black
due to the albumin ﬁlm at the interface. The remaining images show Survanta on a
/expansion cycles. Real time ﬂuorescence movies of the isotherms are available in the
urface pressure, no ﬂuorescence is visible showing that the albumin prevents Survanta
ta (out of focus bright spots) cannot break through the albumin ﬁlm even at a surface
cond Cycle (e) Π=18 mN/m during compression. Survanta breaks through the albumin
s coexist on the interface. (f)Π=16 mN/m during expansion. The Survanta and albumin
all of the albumin. Row 4—Third Cycle (g) Π=26 mN/m during compression. Albumin
cycle Πmax~65 mN/m). (h) Π=15 mN/m during expansion. From the third expansion
mpression. The mottled texture of the ﬁlm is similar to Survanta (a) however the bright
ng to the ﬂocculation and growth of the Survanta aggregates. (j) Π=68 mN/m during
Table 1
Physical properties of varying molecular weight PEG in saline buffer
MW (kDa) 2 Rg (nm) W (0 nm) (kBT) W (4 nm) (kBT) η / ηsol
1.45 3.0 −60.1 0 1.12
3.35 4.8 −65.4 −1.8 1.14
6.0 6.6 −69.3 −10.7 1.19
10.0 8.7 −72.9 −21.4 1.24
20.0 12.8 −78.2 −36.9 1.30
35.0 17.4 −82.7 −49.0 1.43
100.0 31.0 −68.2⁎ –– 2.40
200.0 45.4 −52.1⁎ –– 3.30
Rg is calculated from the scaling law for PEG in water [44]. W(0 nm) and W(4 nm) are
the magnitudes of the depletion attraction in units of kBT at contact (0 nm) and at 4 nm
(roughly the thickness of an albumin ﬁlm) from Eq. (3) for molecular weights up to
35 kDa. ⁎W(0) for 100 and 200 kDa are estimates based on the polymer reference
interaction site model (PRISM) theory of Fuchs and Schweizer for overlapping,
entangled polymers where the maximum value of the depletion attraction occurs at
the polymer overlap concentration [40,41]. Above overlap, the relevant length scale is
no longer Rg but polymer mesh length, ξ, which decreases with increasing
concentration, reducing the range of the depletion attraction. However, this theory
does not predict a distance dependence of the interaction. For each PEG molecular
weight, η /ηsol is the ratio of the zero shear viscosity of the 1% wt. polymer solution to
the viscosity of the buffer measured with a capillary viscometer. η /ηsolN2 is typically
taken to be a rough indication that the polymer solution is above the overlap
concentration. A radius of surfactant aggregate, R, of 500 nm is used for all calculations.
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surface pressure obtained by the Survanta–albumin isotherm (Fig. 3b,
circles) is between that of the 3 μg and 8 μg Survanta isotherms in
Fig. 3a, which gives an estimate of the amount of surfactant actually
adsorbed at the interface. Hence, the effective decrease in surfactant
adsorption in the presence of the energy barrier induced by albumin
for a Survanta concentration of 800 μg is similar to that from a solution
with a concentration 3 μg to a clean interface with no energy barrier.
From Eq. (1), this decrease in adsorption can be used to estimate the
magnitude of the energy barrier: ln 800 μg3 μg

 
= VmaxkBT , or Vmax~5.6 kBT.
Adding PEGwithmolecular weights of 3.35 kDa or greater (Fig. 3b)
to the subphase containing both albumin and PEG has the same effect
as increasing the surfactant concentration on a clean interface (Fig. 3a).
As in Fig. 3a, the shapes of the isotherms are unchanged, just shifted to
the right to larger trough areas with increasing PEGmolecular weight.
This similarity between adding polymers and increasing the surfactant
concentration conﬁrms that surfactant behavior at the interface is not
affected by the albumin and polymer, but rather only the net rate of
adsorption is modiﬁed. The Survanta isotherms shift to the right with
increasing PEG molecular weight yielding a maximum in the surfac-
tant adsorption for 6 kDa up to 35 kDa. For 100 kDa PEG and above, the
isotherm shifts back to the left, indicating that the higher molecular
weight PEG is not as effective at promoting Survanta adsorption.
5. Discussion
Eq. (4) gives the theoretical prediction of the change in surfactant
adsorption relative to a clean interface as a function of the magnitude
of the depletion attraction, which in turn, depends on the polymer
molecular weight and concentration. Fig. 4 shows this relative rate of
surfactant adsorption as a function of PEG molecular weight [13]. The
area/molecule is uniquely determined by the surface pressure for a
given surfactant composition and temperature, which means that the
amount of surfactant adsorbed is proportional to the surface pressure
at a ﬁxed trough area [46]. Hence, we can deﬁne the relative adsorp-
tion (RA) as the difference between the sample surface pressure (Π)Fig. 4. Relative adsorption (RA) of 800 μg Survanta on subphases containing 2 mg/mL
albumin at varying PEGmolecular weights and concentrations.○ 1% wt. PEG;□ 0.5% wt
PEG; △ 0% wt. PEG which has been plotted for comparison purposes. RA is the
difference between the sample surface pressure (Π) and the surface pressure of the
albumin only isotherm (ΠAlb, red curve in Fig. 1b), divided by the difference between
the surface pressure for the saturated isotherm (ΠSat,N1% PEG 10 kDa [13]) and ΠAlb,
RA = P−PAlbPSat−PAlb jA0 . All surface pressures were evaluated by averaging over the same trough
area, A0, denoted by the shaded area in Fig. 3b. Region I (PEG 1.45–3.35 kDa)
corresponds to minimal reversal of surfactant adsorption inhibition, Region II (PEG 6–
35 kDa) corresponds to complete reversal of adsorption inhibition and Region III (PEG
100–200 kDa) corresponds to partial reversal of adsorption inhibition. The dashed line,
where RA depends on the MW0.1 as predicted by Eqs. (1–5), is a good ﬁt to the PEG 1%
wt. data in Region II, consistent with the depletion attraction lowering the energy
barrier to surfactant adsorption. Data points were offset vertically (maximum 5%) to
enhance graph readability.and the surface pressure of the albumin only isotherm (ΠAlb, red curve
in Fig. 1b), divided by the difference between the surface pressure for
the clean surface isotherm, ΠSat (N1% PEG 10 kDa [13]) and ΠAlb,
RA = P−PAlbPSat−PAlb jA0 . All surface pressures were evaluated by averaging over
the same trough area (A0) denoted by the shaded area in Fig. 3b. This
region showed the maximum variation in surface pressure.
Fig. 4 shows three distinct responses as a function of PEG
molecular weight. In Region I, the range of the depletion attraction
(lb2Rgb5 nm) does not sufﬁciently overlap with the maximum in the
repulsive potential Vmax and surfactant adsorption is not signiﬁcantly
increased. Bovine serum albumin is a prolate spheroid of dimensions
4×4×14 nm and forms a monolayer at the air–water interface with a
thickness of 4 nm [39]. The Debye length for electrostatic repulsion in
physiological saline is about 1 nm [38]. Some combination of the
albuminﬁlm thickness and theDebye length deﬁnes the location of the
maximum in the repulsive potential, and hence theminimum range of
a depletion attraction necessary to enhance surfactant adsorption.
Table 1 shows 2Rg for the different molecular weight polymers as well
as the magnitude of the depletion attraction at 4 nm. The range of the
depletion attraction induced by 1.45 kDa PEG (3.0 nm) is less than the
axial dimension of the albuminmolecule, sowe expectminimal effects
on surfactant adsorption as observed (Fig. 4). The range of the 3.35 kDa
PEG depletion attraction (4.8 nm) is about the same as the albumin
dimensions, butW(4 nm) is only −1.8 kBTwhich is smaller than the ~5
kBT repulsive energy barrier determined above [13], so the reversal of
inhibition is less than complete, consistent with Fig. 4.
For the intermediate molecular weight range in Region II, the
depletion interaction is sufﬁciently long-ranged that it overlaps the
repulsive interactions and leads to enhanced surfactant adsorption.
From Eqs. (1–4), the relative adsorption with albumin and PEG in the
subphase compared to a clean (diffusion-limited) interface should be
an exponential function of PEG molecular weight:
ln
dC=dtAlb + Poly
dC=dt
 
= ln RAð Þ = − PDA + EElect+Wmaxð Þ=kBT e g + bMW0:1
ð5Þ
in which β and γ are constants for a given Survanta and albumin con-
centration. For 1%wt. PEG over themolecular weight range of 6–35 kDa
(Region II), thedashed line in Fig. 4, (RA)∝MW 0.1,ﬁts thedata quitewell.
Though there is more scatter in the data, the scaling law also holds
reasonably well for 0.5% wt. PEG over this range of molecular weights.
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contrast to the scaling predicted by Eq. (5). From Table 1, the ratio of
polymer solution viscosity to the solvent (water) viscosity, η /ηsol, for
1% wt. polymers in Region III exceeds the overlap criterion (η /ηsolN2)
for these PEG molecular weights. As the polymer solution approaches
the overlap concentration and crosses into the semi-dilute regime, the
polymer is no longer isolated random coils with characteristic length
scale Rg but instead an entangled polymer mesh with characteristic
length scale ξ. Above overlap, the Asakura and Oosawa (AO) hard
sphere model for the depletion attraction must be modiﬁed by the
polymer reference interaction site model (PRISM) of Fuchs and
Schweizer to account for the competition between the increasing
polymer concentration and decreasing polymermesh length, ξ [35,36].
For a dilute colloidal system with a large aspect ratio between the
colloid (R~500 nm) and polymer (Rg~20 nm), PRISM predicts that the
magnitude of the depletion attraction will plateau at roughly the
polymer overlap concentration. 200 kDa PEG reaches its overlap at
signiﬁcantly lower concentrations (~0.5% wt.) than 10 kDa PEG (~4.0%
wt.), which explainswhy the PEG200 kDa depletion attraction is lower
in magnitude (Table 1) and yields lower RA values for PEG molecular
weights in Region III. The plateau of the depletion attraction at roughly
the overlap concentration demonstrates an upper limit for the effec-
tiveness of a polymer of a given molecular weight. Any additional
polymer above the overlap concentration no longer increases the
depletion attraction, but does greatly increases the solution viscosity.
Deff in Eq. (1) is inversely proportional to the solution viscosity, the net
rate of adsorption will decrease above the overlap concentration as
shown in Fig. 4.
Our results are consistent with those of Yu et al.who showed that
increasing PEG molecular weight (from 3.35–35 kDa) enhanced the
rate of bovine lipid extract surfactant absorption to a clean interface
[20], while higher molecular weight PEG (300 kDa) did not enhance
adsorption. Surface force apparatus (SFA) measurements between
mica-supported lipid bilayers in 10% wt. 1 kDa PEG yielded a force–
distance proﬁle similar to pure water, indicating at this low molecular
weight, the PEG does not generate a depletion attraction [56]. Kuhl et
al. also showed a concentration dependant increase in the adhesion
force between lipid bilayers in the SFA for solutions containing 8 or
10 kDa PEG, which quantitatively agrees with that expected for a
depletion attraction between the bilayers [56]. Alig et al. have shown
the re-adsorption of anionic lipids to the interface after collapse was
proportional to the subphase ionic strength, showing that an electro-
static barrier exists for anionic lipids and that this barrier could be
modiﬁed via charge screening [21]. Survanta was used as the model
clinical surfactant in these experiments, however, the depletion
attraction theory predicts enhanced surfactant adsorption is indepen-
dent of surfactant composition. This is consistent with previous results
that showed clinical and native lung surfactants of varying composi-
tion all showed resistance to serum inhibition in the presence of PEG
[40]. However, the theory does predict a dependence on surfactant
aggregate size (R in Eq. (3)); if different surfactant preparations have
different aggregate sizes, differences in polymer-enhanced adsorption
would be expected.
Although the compression and expansion cycles on the Langmuir
trough are slow (8 min/cycle) compared to physiological rates (3 s/
cycle), previous pulsating bubble surfactometer results show that
10 kDa PEG also reverses serum protein inhibition at physiological
rates [40]. This correspondence likely holds for over the entire PEG
molecular weight range and the same Relative Adsorption vs. PEGMW
results presented in Fig. 4 likely hold. In a clinically relevant situation,
the polymer is added to replacement lung surfactants and the resulting
preparation is instilled intratracheally as rescue therapy after lung
injury. Lung function of animalswith lung injury ismarkedly improved
when polymers are added to clinical surfactants [6,7,27,29]. In our
experiments, the PEG is added to the subphase instead of the sur-
factant to ensure a uniform PEG subphase concentration. There is goodcorrespondence between the concentrations of PEG necessary to
reverse serum protein inhibition in our Langmuir trough experiments
(1% wt.) and the PEG concentration that is utilized in animal injury
models (5%wt. for 10 kDa PEG) [6].While the polymer concentration is
higher in the animal injury models, this concentration is based on the
instilled surfactant volume (~1.2 mL [6]) and will be diluted by the
lining ﬂuid in the airways and alveoli.
6. Conclusions
These and our previous results [13] show that the PEG just below the
overlap concentration optimizes the depletion attraction, and hence
surfactant adsorption for a given molecular weight PEG in the presence
of the competitive adsorption of albumin.While molecular weights of 6
–35 kDa are optimal for PEG at 1% wt., other polymers may exhibit
optimum molecular weights which are larger or smaller depending on
composition, overlap concentration and charge. For example, hyalur-
onan (HA), an anionic natural polysaccharide that is secreted by alveolar
epithelial cells, of molecular weight 100–1240 kDa has been shown to
reverse surfactant inhibition in vitro [25] at much lower concentrations
than PEG. If both surfactant aggregates and polymer have the same
charge (net anionic), the effective depletion attraction has a longer
range. The electrostatic repulsion between the large and small particles
increases the effective radius of both the surfactant aggregates and
polymer by roughly the Debye length, additionally increasing surfactant
adsorption [17]. HA occurs in the lung epithelial ﬂuid at concentrations
of 4000 μg/L with a molecular weight of 220 kDa, in contrast to the
2000 kDa HA in cartilage and 7000 kDa HA in synovial ﬂuid [57],
suggesting an optimized HA molecular weight in the lung. During lung
injury and disease, HA can be broken down by enzymatic action to
produce smaller molecular weight fragments (1.6 kDa–10 kDa) [57].
Similar to Region I of Fig. 4, the depletion attraction generated by these
low molecular weight fragments may lack sufﬁcient range to enhance
surfactant adsorption, especially in the presence of serum proteins. Our
results demonstrate the existence of an optimum PEGmolecularweight
range for depletion attraction-enhanced surfactant adsorption and
suggest that deviating from that optimum range can have deleterious
results.
Fluorescence images conﬁrm that albumin on the interface pre-
vents Survanta bilayer aggregates from reaching the air–water inter-
face, which appears to be necessary to initiate the conversion from
bilayers to monolayers. Survanta can approach the albumin-covered
interface, but without the added push from the polymer-induced
depletion attraction, Survanta remains below the interface indeﬁnitely
and never spreads to form a monolayer. However, once the Survanta
has broken through to the albuminmonolayer, albumin and surfactant
coexist at the air–water interface in immiscible domains. The albumin
domains remain at the interface up to surface pressures (~55–65 mN/
m) well above the equilibrium surface pressure of a pure albumin ﬁlm
(~20 mN/m) before ﬁnally being squeezed-out from the interface.
Survanta aggregates remain tethered to the interface even aftermono-
layer formation, providing a reservoir of surfactant for replenishing the
interface on expansion. In the presence of polymer, the Survanta
aggregates are signiﬁcantly larger thanwithout polymer; the depletion
attraction leads to surfactant aggregation and ﬂocculation in solution
in addition to enhancing surface adsorption [17,40]. The larger reser-
voir of surfactant at the interface likely also acts to enhance surfactant
adsorption, even in the absence of albumin inhibition, as observed by
Yu et al. [20].
An additional factor to consider in future treatments is that the
osmotic pressure of the polymer-surfactant solution should be
minimized to prevent inﬁltration of liquid into the lungs during any
potential ARDS treatment [58]. Hence, the lowest concentration of the
highest molecular weight polymer that provides the necessary
inhibition reversal should be used; the optimal PEG molecular weight
for surfactant inhibition reversal is therefore likely to be around
2040 P.C. Stenger et al. / Biochimica et Biophysica Acta 1778 (2008) 2032–204035 kDa [28]. A caveat to this optimalmolecularweight is that it depends
on the concentration of the polymer; the use of higher polymer
concentrations (N1%PEG) results in overlap and a correspondingplateau
in enhanced surfactant adsorption at a lower polymermolecularweight.
A further advantage of using 35 kDa PEG compared to smallermolecular
weights is the increased range of the depletion attraction (2Rg). Other
serum proteins such as ﬁbrinogen also competitively adsorb with lung
surfactant lipids; ﬁbrinogen is larger than albumin with dimensions of
5×5×46 nm [59]. While the exact orientation of ﬁbrinogen at the air–
liquid interface is unknown, the higher molecular weight PEG can likely
generate a depletion attraction with sufﬁcient range and magnitude to
enhance surfactant adsorption. Considering all of these factors, the data
suggest that using the largest molecular weight polymer at concentra-
tions near the overlap concentrationwill enhance surfactant adsorption
with the smallest osmotic pressure and largest range. Reversing
surfactant inhibition due to the competitive adsorption of serum
proteinswith hydrophilic polymers is likely to be one ofmany necessary
steps to successfully treat ARDS.
Note Added in Proof
Increasing surfactant adsorption is a necessary, but not sufﬁcient
condition to reverse surfactant inactivation. If the adsorbed surfactant
is compromised by changes in the chemical composition, lower
surface tensions will not be achieved regardless of the amount
adsorbed [60].
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